K SEC filing received on January 31, 2025, that the company has been notified by The Nasdaq Stock Market, LLC about its failure to meet the minimum bid requirement for continued listing on the Nasdaq ...

Findings suggested that the BB305 LVV vector was present in the AML blast cells, but there was not sufficient information to determine causality. Vector insertion in the AML cells from this ...

Moreover, AML cells themselves are highly heterogeneous ... They have also observed some early evidence of blast cell reduction, although evidence of activity is never the primary objective ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The ...

A treatment strategy for acute myeloid leukemia could involve ... miR-142 deficit in leukemic stem cells has been associated with chronic myeloid leukemia blast crisis. Here the authors show ...

AML is also characterized by particularly aggressive progression; if left untreated, patients can succumb to disease within weeks. As can be inferred from their names, different blast cell populations ...

This highlights the uniqueness of our analysis in both the detection of AML and the use of whole images rather than leukocyte/blast-cell images. Our study has several limitations. First, a high level ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies, reported ...